STERIS plc (STE)

NYSE: STE · IEX Real-Time Price · USD
189.73
+2.27 (1.21%)
Mar 30, 2023, 10:45 AM EDT - Market open
1.21%
Market Cap 18.83B
Revenue (ttm) 4.78B
Net Income (ttm) -27.93M
Shares Out 99.28M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE 23.26
Dividend $1.84 (0.97%)
Ex-Dividend Date Feb 23, 2023
Volume 37,781
Open 189.32
Previous Close 187.46
Day's Range 188.78 - 190.11
52-Week Range 159.21 - 255.93
Beta 0.85
Analysts Buy
Price Target 224.40 (+18.27%)
Earnings Date May 9, 2023

About STE

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in th... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 1, 1992
Employees 16,000
Stock Exchange NYSE
Ticker Symbol STE
Full Company Profile

Financial Performance

In 2022, Steris's revenue was $4.59 billion, an increase of 47.55% compared to the previous year's $3.11 billion. Earnings were $243.89 million, a decrease of -38.63%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for STE stock is "Buy." The 12-month stock price forecast is $224.4, which is an increase of 18.27% from the latest price.

Price Target
$224.4
(18.27% upside)
Analyst Consensus: Buy
Stock Forecasts

News

STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y

Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.

1 month ago - Zacks Investment Research

Steris (STE) Lags Q3 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of -9.01% and 4.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

STERIS Announces Financial Results for Fiscal 2023 Third Quarter

DUBLIN, IRELAND, Feb. 08, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 third quarter ended December 31, 2022. Reve...

1 month ago - GlobeNewsWire

STERIS Declares $0.47 per share Dividend

DUBLIN, IRELAND, Feb. 01, 2023 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share....

2 months ago - GlobeNewsWire

STERIS to Host a Conference Call for Fiscal 2023 Third Quarter Financial Results on February 9, 2023

DUBLIN, IRELAND, Jan. 25, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 third quarter finan...

2 months ago - GlobeNewsWire

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.

3 months ago - Zacks Investment Research

STERIS (STE) Gains on New Orders, FX Impact Dents Growth

STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.

3 months ago - Zacks Investment Research

STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase

Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.

4 months ago - Zacks Investment Research

Steris (STE) Q2 Earnings and Revenues Miss Estimates

Steris (STE) delivered earnings and revenue surprises of -0.50% and 1.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

STERIS Announces Financial Results for Fiscal 2023 Second Quarter

DUBLIN, IRELAND, Nov. 09, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 second quarter ended September 30, 2022. Re...

5 months ago - GlobeNewsWire

STERIS to Host a Conference Call for Fiscal 2023 Second Quarter Financial Results on November 10, 2022

DUBLIN, IRELAND, Oct. 25, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 second quarter fina...

5 months ago - GlobeNewsWire

What's Driving The Growth For STERIS Stock?

STERIS stock (NYSE: STE), a healthcare company focused on infection prevention, has seen a 29% fall this year, slightly underperforming the broader S&P500 index, down 21%.

6 months ago - Forbes

Steris (STE) Down 0.8% Since Last Earnings Report: Can It Rebound?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays

Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.

8 months ago - Zacks Investment Research

STERIS (STE) Q1 Earnings Match Estimates, EPS View Down

STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.

8 months ago - Zacks Investment Research

Steris (STE) Meets Q1 Earnings Estimates

Steris (STE) delivered earnings and revenue surprises of 0% and 5.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

STERIS Announces Financial Results for Fiscal 2023 First Quarter

DUBLIN, IRELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2023 first quarter ended June 30, 2022. Revenue ...

8 months ago - GlobeNewsWire

STERIS Raises Dividend to $0.47 per share

DUBLIN, IRELAND, July 28, 2022 (GLOBE NEWSWIRE) --  STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.47 per share....

8 months ago - GlobeNewsWire

3 MedTech Stocks That are Likely to Beat This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.

Other symbols: IDXXTMO
8 months ago - Zacks Investment Research

Steris (STE) Earnings Expected to Grow: Should You Buy?

Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

STERIS to Host a Conference Call for Fiscal 2023 First Quarter Financial Results on August 3, 2022

DUBLIN, IRELAND, July 20, 2022 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2023 first quarter finan...

9 months ago - GlobeNewsWire

How Much Upside is Left in Steris (STE)? Wall Street Analysts Think 29%

The mean of analysts' price targets for Steris (STE) points to a 29.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...

9 months ago - Zacks Investment Research

3 Reasons Why Steris (STE) Is a Great Growth Stock

Steris (STE) possesses solid growth attributes, which could help it handily outperform the market.

9 months ago - Zacks Investment Research

Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock?

10 months ago - Zacks Investment Research

Here's Why You Should Hold STERIS (STE) Stock in Your Portfolio

Investors are optimistic about STERIS (STE) due to its strong fiscal fourth-quarter results.

11 months ago - Zacks Investment Research